G1T38
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for G1T38, covering 2017-06-14 to 2023-05-01. Get the full timeline:
Most recent: Clinical Trial Update: G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer [Phase 1, Phase 2]